BioClinica announced that Amarin Corporation has chosen the eClinical suite from BioClinica to capture and manage clinical data for their Phase IIIb cardiology clinical trial, including: electronic data capture (EDC) and data management, interactive response technology (IRT/IVR/IWR), and clinical trial management (CTMS) solutions. Amarin Corporation is a late-stage biopharmaceutical company focused on the treatment of cardiovascular disease. The study is planned to involve approximately 300 sites and 8,000 patients globally.
BioClinica’s Trident IWR and EDC systems were selected based on BioClinica’s advanced technology portfolio, experience with large global trials; and cardiology expertise. BioClinica was able to build and deploy the study within 4 weeks.
“We are pleased that Amarin’s clinical development team selected an integrated solution from BioClinica that will seamlessly share essential clinical data while streamlining their clinical data and site management processes,” said Peter Benton, BioClinica’s President of eClinical Solutions. "In the last two quarters we have seen sponsors and CROs significantly increase their interest and investment in solutions that are not only “best-in-class” but also reduce the cost and hassle of unifying their clinical data to both manage their trials as well as readying their data for analysis.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.